Biotech

All Articles

Zephyrm looks for Hong Kong IPO to money stage 3 tissue treatment tests

.Zephyrm Bioscience is actually gusting towards the Hong Kong stock exchange, filing (PDF) for an IP...

Frazier Life Sciences gets $630M for tiny, mid-cap biotechs

.Frazier Everyday life Sciences has sourced a further $630 million for its own fund paid attention t...

GigaGen gathers as much as $135M BARDA dollars to hammer botulism

.Antitoxin aficionado GigaGen, a subsidiary of Spanish biopharma Grifols, is actually ramping up its...

GPCR company Septerna declare IPO on stamina of preclinical information

.Septerna is about to find out exactly how a biotech without "any sort of significant scientific inf...

Kurma closes to begin with $154M haul for largest biotech fund as yet

.International VC firm Kurma Partners has revealed its own most up-to-date biotech fund, with 140 mi...

Prothena markets one exec while yet another places-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial management hirings, shootings...

Editas capitalize Tip Cas9 licensing liberties for $57M

.Against the background of a Cas9 patent battle that declines to die, Editas Medicine is cashing in ...

Ultragenyx fine-tunes genetics therapy dosing to dial up efficiency

.A minority of people taking Ultragenyx Pharmaceutical's Wilson illness gene therapy UX701 have come...

Biopharma discharge cost stabilizes in Q3: Tough Biotech evaluation

.As summer months heat relies on cool winds, hopes that this year would carry wide-spread sector all...

J &amp J loses period 2 dengue candidate in newest change coming from injections

.Johnson &amp Johnson's deprioritization of its own infectious disease pipe has actually declared an...